Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03509064
Other study ID # NI17025J
Secondary ID 2017-A02858-45
Status Recruiting
Phase
First received
Last updated
Start date January 11, 2019
Est. completion date July 11, 2023

Study information

Verified date August 2020
Source Assistance Publique - Hôpitaux de Paris
Contact Damien SÈNE, MD, PhD
Phone +33149956380
Email damien.sene@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

BACKGROUND Sjögren's syndrome is an autoimmune disease whose prevalence is estimated between 200 and 500 patients per 100,000 persons in France (120 to 500,000 patients). It affects women (90%) between 40 and 60 years of age and main manifestations are generalized sicca syndrome (ocular, oral, cutaneous) and arthralgia. In 20% of cases, Sjögren's syndrome is associated with peripheral neuropathies, and the most common form is painful small fiber neuropathy (SFN). SFNs are mainly featured by neuropathic pain including burns (90%), numbness (87.5%), tingling (72.5%), electric shocks (70%) and tingling (82.5%) and also autonomic disorders (50 to 70%). However, there are still important issues that deserve to be investigated by clinical and basic research. Among these issues, this study will focus on: - The impact of SFN on the quality of life of patients with Sjögren's syndrome. - The medico-economic impact of the SFN taking into account the repercussions on the quality of life, including professional life, usual care cost (analgesics, medical and paramedical consultations, hospitalizations or emergency). EXPECTED RESULTS - Confirmation of the major impairment in the quality of life of patients with Sjogren-associated SFN - Analysis of correlations to highlight or not clinical or biological factors associated with quality of life impairment. - Evaluation of the cost attributed to the presence of an SFN in patients with Sjögren's syndrome and the pharmaco-economic interest of conventional therapeutic management (analgesic treatment, consultation pain) compared to the cost of more aggressive immunomodulatory treatments.


Description:

Primary objective: Identify the predictors of quality of life impairment and costs of management of patients with Sjögren's syndrome and small fiber neuropathy (SFN). Secondary objectives : 1. Hospital, drug and city-care costs 2. Distribution of cost items 3. Part of costs attributable to pSS-associated SFN 4. Loss of quality of life attributable to pSS-associated SFN 5. Relationship between the domains of the EQ 5D questionnaire and the other specific quality of life questionnaires 6. Association of the EQ 5D and other questionnaires with the costs (part of the costs variance that might be explained by the quality of life). PATIENTS AND METHODS / Study population Monocentric study in the Department of Internal Medicine of Lariboisière Fernand Widal Hospital. All included patients fulfilled 2002-criteria of primary Sjogren syndrome. Patients are classified into 2 arms: Arm1: patients with Sjögren's syndrome and definite SFN Arm2 ( Control Group) : patients with Sjögren's syndrome and WITHOUT clinical and paraclinical arguments for peripheral neuropathy RESARCH PROCESS This study will be based on the delivery and analysis of validated questionnaires (collection sheet) in chronic diseases, pains or Sjögren's syndrome: - SF-36 for quality of life, - DN4 questionnaire to estimate the probability of neuropathic pain - EQ5D Health questionnaire - ESSPRI (4 questions): Sjogren-patient questionnaire - PROFAD-SSI (19 questions), to assess tiredness, discomfort, pain and dryness symptoms associated with Sjögren's syndrome. - The economic evaluation will be done after the inclusion visit and will be based on the collection of care resources consumed by the patients during a period of 6 months


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 11, 2023
Est. primary completion date July 11, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Definite primary Sjögren syndrome - Age over 18 years - No biologics nor immunoglobulin therapy during the 6 months before study onset Arm 1: patients with a small fiber neuropathy defined by the presence of a clinical AND one paraclinical abnormality - (i) Clinical signs of small fibers involvement: thermo-algic sensory deficit or autonomic dysfunction or neuropathic pain with DN4 =4; - AND - (ii) Small fibers neurophysiological abnormalities (QST, laser evoked potentials, autonomic nervous system tests (sympathetic skin response test or Sudoscan®) - OR - (iii) abnormal intraepidermal nerve fiber density (skin biopsy) Arm2 (control group): patients without signs of peripheral neuropathy (small or large fiber) Exclusion Criteria: - Presence of other causes of peripheral neuropathy - Acquired: Diabetes, AL amyloidosis, Alcoholism, celiac disease, Drugs, toxic, HIV, Sarcoidosis, systemic vasculitis, Guillain-Barré syndrome. - Hereditary: Transthyretin hereditary amyloidosis (TTR), hereditary sensory and autonomic neuropathy (HSAN), Fabry's disease - Patients with impaired thermo-algic sensitivity and / or dysautonomia and / or pain with DN4 = 4 AND normal diagnostic tests (normal neurophysiological tests AND normal skin biopsy) are excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Collection sheet
Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet

Locations

Country Name City State
France Département de Médecine Interne - Hôpital Lariboisière Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris LFB BIOMEDICAMENTS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure of quality of life impairment by SF 36 scale For each of the eight domains that the SF36 measures an aggregate percentage score is produced. The percentage scores range from 0% (lowest or worst possible level of functioning) to 100% (highest or best possible level of functioning).
It easy to set up a computerised database (e.g., in MS Excel or similar) to calculate the percentages and averages
Month 3
Secondary Hospitalization costs' using a collection sheet during a period of 6 months
Secondary Drug costs' using a collection sheet during a period of 6 months
Secondary City care costs' using a collection sheet during a period of 6 months
Secondary Distribution of cost items using a collection sheet during a period of 6 months
Secondary Part of costs attributable to primary Sjögren syndrome-associated small fiber neuropathy. using a collection sheet during a period of 6 months
Secondary Loss of quality of life attributable to primary Sjögren syndrome-associated small fiber neuropathy. The loss of quality of life is appreciated by using a collection sheet (detailed in the research process) during a period of 6 months
Secondary Evaluation of the domains of the EQ 5D questionnaire using a collection sheet during a period of 6 months
Secondary Evaluation of specific quality of life questionnaire using a collection sheet during a period of 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A